GNT0003

DRUG2 trials

Sponsors

Genethon

Conditions

Crigler-Najjar Syndrome

Phase 2

Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

RecruitingNCT06518005

GenethonCrigler-Najjar Syndrome

Start: 2024-11-08End: 2030-09-30Target: 3Updated: 2024-12-03

Unknown Phase

Gene Therapy for Severe Crigler Najjar Syndrome

RecruitingNCT03466463

GenethonCrigler-Najjar Syndrome

Start: 2018-03-19End: 2030-03-30Target: 17Updated: 2023-03-28

Related Papers

Gene Therapy in Patients with the Crigler–Najjar Syndrome

New England Journal of Medicine2023-08-1657 citations

Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy

Genetics in Medicine2020-05-1421 citations

Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome

Human Gene Therapy2019-09-1060 citations